MONTREAL, QC and CAMBRIDGE, ENGLAND--(Marketwire - April 09, 2008) - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces that ProMetic has signed a Letter of Intent ("LOI") to acquire the American Red Cross' ("ARC") common stock holding in Pathogen Removal and Diagnostic Technologies Inc. ("PRDT"), the joint venture established by ProMetic and ARC in 2002 to develop and commercialize products to diagnose and reduce pathogens in blood, blood derivatives, biopharmaceuticals and other biological products.